References
- All cancers (excluding nonmelanoma skin cancer) estimated incidence, mortality and prevalence worldwide in 2012. World Health Organization. 2 Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=all.2016.08.29
- Chiu PH, Hsieh HY, Wang SC. Prescriptions of traditional Chinese medicine are specific to cancer types and adjustable to temperature changes. Plos One. 2012;7:e31648.
- Jia L, Ma S, Hou X, et al. The synergistic effects of traditional Chinese herbs and radiotherapy for cancer treatment. Oncol Lett. 2013;5:1439–1447.
- Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer. 2004;4:737–747.
- Bischoff P, Altmeyer A, Dumont F. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers. Expert Opin Ther Pat. 2009;19:643–662.
- Cowell IG, Durkacz BW, Tilby MJ. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectasia mutated. Biochem Pharmacol. 2005;71:13–20.
- Nie J, Zhao C, Deng L, et al. Efficacy of traditional Chinese medicine in treating cancer (Review). Biomed Reports. 2016;4:3–14.
- Lawenda BD MD. Response to “Radiation therapeutic gain and Asian botanicals,” by Stephen Sagar. Integr Cancer Ther. 2010;9(1):14–15.
- Danrong L, Huaxin H Application of anthraquinones compound separated from polygonum multiflorum thumb using as radiation sensitizer. CN200610020058.8. 2006.
- Shudong Y, Fenye L, Xiaoxing L, et al. Chinese herbal preparation for nasopharynx cancer radiosensitization and preparation method thereof. CN201510718362.9. 2015.
- Qi F, Li A, Inagaki Y, et al. Chinese herbal medicines as adjuvant treatment during chemo- or radio-therapy for cancer. Biosci Trends. 2010;4:297–307.
- Zeng YC, Wu R, Xing R, et al. Radiation-enhancing effect of sodium glycididazole in patients suffering from non-small cell lung cancer with multiple brain metastases: a randomized, placebo-controlled study. Cancer/Radiothérapie. 2016;20(2016):187–192.
- Wenwei S, Xinquan G, Shi G, et al. Therapeutic safety evaluation of sodium glycididazole combined with 131I radiotherapy for differentiated thyroid carcinoma. Nucl Sci Tech. 2011;22(2011):212–216.
- Cuixia D, Hong Z, Shuai X, et al. Application of diallyl disulfide in preparation of heavy ion radiation sensitizing drug. CN201410005021.2. 2014.
- Qiang Y, Yaqiu L, Zulong L, et al. Sulfonamide compound and medicinal compositions thereof, and preparation methods and applications thereof. CN201210004143.0. 2012.
- Maggie JR, Kalpana SJ, Nikhil KH, et al. Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer. CN201080027763.5. 2010.
- Rongqing H, Bingkun X, Jianyun Y, et al. Application of 3-acylamino-1,2,4-phentriazines to preparation of tumor sensitizer. CN201210291164.5. 2012.
- Li M, Jiang T, Zhuang X, et al.Method for synthesizing nicotinyl amino acids and sensitizing effect thereof to tumor radiotherapy. CN200710057169.0. 2007.
- Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897–907.
- Tian H, Gao Z, Li H, et al. DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2015;358:8–16.
- Salovska B, Fabrik I, Durisova K, et al. Radiosensitization of human leukemic HL-60 cells by ATR kinase inhibitor (VE-821): phosphoproteomic analysis. Int J Mol Sci. 2014;15:12007–12026.
- Raleigh DR, Haas-Kogan DA. Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. Future Oncol. 2013;9:219–233.
- Mladenov E, Magin S, Soni A, et al. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013;3:113.
- Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol. 2010;31:363–372.
- Szumiel I. Ionizing radiation-induced oxidative stress, epigenetic changes and genomic instability: the pivotal role of mitochondria. Int J Radiat Biol. 2015;91:1–12.
- Krause M, Dubrovska A, Linge A, et al. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63–73.
- Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003;3:117–129.
- Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer. 2002;2:647–656.
- Dejean LM, Martinez-Caballero S, Manon S, et al. Regulation of the mitochondrial apoptosis-induced channel, MAC, by BCL-2 family proteins. Biochim Biophys Acta. 2006;1762:191–201.
- Dogu Y, Diaz J. Mathematical model of a network of interaction between p53 and Bcl-2 during genotoxic-induced apoptosis. Biophys Chem. 2009;143:44–54.
- Jiang X, Wang X. Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1. J Biol Chem. 2000;275:31199–31203.
- Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91:479–489.
- Harms K, Nozell S, Chen X. The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci. 2004;61:822–842.
- Jia LT, Chen SY, Yang AG. Cancer gene therapy targeting cellular apoptosis machinery. Cancer Treat Rev. 2012;38:868–876.
- Houston A, O’Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 2004;4:321–326.
- Rockwell S, Dobrucki IT, Kim EY, et al. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Curr Mol Med. 2009;9:442–458.
- Ghattass K, Assah R, El-Sabban M, et al. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy. Curr Cancer Drug Targets. 2013;13:670–685.
- Hall E, Giaccia A.  Radiobiology for the radiologist. 7th ed. Philadelphia: Lippincott Williams & Wilkins (LWW); 2011.
- Hennessey D, Martin LM, Atzberger A, et al. Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells. Urol Oncol. 2013;31:1106–1116.
- Lin A, Maity A. Molecular pathways: a novel approach to targeting hypoxia and improving radiotherapy efficacy via reduction in oxygen demand. Clin Cancer Res. 2015;21:1995–2000.
- McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clinical Oncology. 2007;19:427–442.
- Gao LL, Li FR, Jiao P, et al. Paris chinensis dioscin induces G2/M cell cycle arrest and apoptosis in human gastric cancer SGC-7901 cells. World J Gastroenterol. 2011;17:4389–4395.
- Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev. 2009;109:2974–2988.
- Weinberg WC, Denning MF. P21Waf1 control of epithelial cell cycle and cell fate. Crit Rev Oral Biol Med. 2002;13:453–464.
- Smits VA, Klompmaker R, Vallenius T, et al. p21 inhibits Thr161 phosphorylation of Cdc2 to enforce the G2 DNA damage checkpoint. J Biol Chem. 2000;275:30638–30643.
- Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good Targets? Nature Reviews Cancer. 2007;7:495–507.
- Li YX, Sun LQ, Weber-Johnson K, et al. Potentiation of cytotoxicity and radiosensitization of (E)-2-deoxy-2’-(fluoromethylene) cytidine by pentoxifylline in vitro. Int J Cancer. 1999;80:155–160.
- Jingbo W Anti-tumor bioactive substance and preparation method thereof. CN201310308948.9. 2013.
- Su XY, Liu PD, Wu H, et al. Enhancement of radiosensitization by metal-based nanoparticles in cancer radiation therapy. Cancer Biol Med. 2014;11:86–91.
- Butterworth KT, McMahon SJ, Currell FJ, et al. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale. 2012;4:4830–4838.
- Tillement O, Roux S, Perriat P, et al. Use of lanthanide-based nanoparticles as radiosensitizing agents. CN200880112101.0. 2008.